Cellectis Logo.png
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023 16:30 ET | Cellectis Inc.
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Logo.png
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023 07:10 ET | Cellectis Inc.
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and...
Global Cellular Immunotherapy Market
Cellular Immunotherapy (CAR T Cell Therapy, Dendritic Cell Therapy) Market Trends/Analysis Report 2022
January 06, 2023 06:03 ET | Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by...
22157.jpg
Global CAR-T Cell Therapy Market Report 2023: Remarkable Efficacy of CAR-T Therapy Against Blood Cancers Fuels Adoption
January 04, 2023 07:38 ET | Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2023" report has been added to ResearchAndMarkets.com's offering. ...
CAR T-Cell Therapy Market
Insights on the CAR T-Cell Therapy Global Market to 2031 - by Drug Type, Indication, End-user and Region
January 04, 2023 05:48 ET | Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "CAR T-Cell therapy Market By Drug type, By Indication, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added...
Cellectis Logo.png
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022 16:30 ET | Cellectis Inc.
The credit facility will enable Cellectis to support the development of its UCART product candidates pipelineThe credit facility consists of three tranches of €20 million, €15 million, and €5 million...
Picture1.png
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
December 21, 2022 16:01 ET | Autolus Therapeutics plc
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today...
MustangBioLogo.jpg
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
December 19, 2022 08:30 ET | Mustang Bio, Inc.
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE...
Cellectis Logo.png
Monthly information on share capital and company voting rights
December 16, 2022 16:30 ET | Cellectis Inc.
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Picture1.png
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
December 12, 2022 10:00 ET | Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...